MAIA Biotechnology's THIO Gets US FDA Rare Pediatric Disease Designation to Treat Pediatric High-Grade Gliomas-March 2024-www.financetom.com

MAIA Biotechnology's THIO Gets US FDA Rare Pediatric Disease Designation to Treat Pediatric High-Grade Gliomas

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

MAIA Biotechnology's THIO Gets US FDA Rare Pediatric Disease Designation to Treat Pediatric High-Grade Gliomas

Dec 16, 2024 7:04 AM

09:46 AM EST, 12/16/2024 (MT Newswires) -- MAIA Biotechnology ( MAIA ) said Monday its investigational telomere-targeting agent THIO received a rare pediatric disease designation from the Food and Drug Administration to treat pediatric-type diffuse high-grade gliomas.

The company partnered with Only Orphans Cote for THIO's designation request, it added.

MAIA said that THIO is currently in clinical development for evaluating its activity in non-small cell lung cancer.

Shares of the company were up 7% in recent Monday trading.

Price: 2.14, Change: +0.14, Percent Change: +7.00

Previous page： Dundee Wins CRA Tax Appeal, Expects $12.2 Million Refund Plus Interest Next page： BRIEF-N2OFF Announces Closing of Merger with Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Dundee Wins CRA Tax Appeal, Expects $12.2 Million Refund Plus Interest

Oct 23, 2025

08:22 AM EDT, 10/23/2025 (MT Newswires) -- Dundee (DC-A.TO) said Thursday it has been successful in its appeals against certain reassessments issued by the Canada Revenue Agency (CRA). The disputed assessments were for the 2014 tax year for Dundee and its subsidiary Dundee Resources. The Tax Court, which allowed the appeals, has referred the matter back to the Minister of...

BRIEF-N2OFF Announces Closing of Merger with Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

Oct 23, 2025

Oct 23 (Reuters) - N2OFF Inc ( NITO ): * N2OFF ANNOUNCES CLOSING OF MERGER WITH DRUG DISCOVERY COMPANY TARGETING RESISTANT CANCERS INCLUDING PANCREATIC AND NON-SMALL CELL LUNG CANCER Source text: Further company coverage: ...

Heritage Financial Q3 Adjusted Earnings, Revenue Rise

Oct 23, 2025

08:24 AM EDT, 10/23/2025 (MT Newswires) -- Heritage Financial ( HFWA ) reported Q3 adjusted earnings Thursday of $0.56 per diluted share, up from $0.45 a year earlier. Analysts polled by FactSet expected $0.55. Revenue for the quarter ended Sept. 30, expressed as the sum of net interest income and total noninterest income, was $65.7 million, up from $54.8 million...

CenterPoint beats profit estimates on industrial power demand, regulatory recovery

Oct 23, 2025

(Reuters) -U.S. utility CenterPoint Energy ( CNP ) on Thursday posted a higher-than-expected third-quarter profit, driven by regulatory recovery and rising industrial demand, including new AI data center loads in Houston, Texas. The industrial throughput in its Houston Electric segment has risen over 11% year-to-date. The Greater Houston area is experiencing strong economic momentum, supported by one of the most...